307 related articles for article (PubMed ID: 29208326)
1. A review on the antagonist Ebola: A prophylactic approach.
Khan FN; Qazi S; Tanveer K; Raza K
Biomed Pharmacother; 2017 Dec; 96():1513-1526. PubMed ID: 29208326
[TBL] [Abstract][Full Text] [Related]
2. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.
Dhama K; Karthik K; Khandia R; Chakraborty S; Munjal A; Latheef SK; Kumar D; Ramakrishnan MA; Malik YS; Singh R; Malik SVS; Singh RK; Chaicumpa W
Front Immunol; 2018; 9():1803. PubMed ID: 30147687
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.
Soni M; Tulsian K; Barot P; Vyas VK
Recent Adv Antiinfect Drug Discov; 2024; 19(4):276-299. PubMed ID: 38279760
[TBL] [Abstract][Full Text] [Related]
4. Development of therapeutics for treatment of Ebola virus infection.
Li H; Ying T; Yu F; Lu L; Jiang S
Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
[TBL] [Abstract][Full Text] [Related]
5. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets.
Fanunza E; Frau A; Corona A; Tramontano E
Infect Disord Drug Targets; 2019; 19(4):362-374. PubMed ID: 30468131
[TBL] [Abstract][Full Text] [Related]
6. The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.
Wu W; Liu S
Curr Top Med Chem; 2017; 17(3):361-370. PubMed ID: 27572081
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Review on Ebola (EBOV) Virus: Future Prospects.
Khan S; Muhammad ; Rauf A; Khan A; Rizwan M; Patel S; Khan H; Mahasneh AM; Mubarak MS
Infect Disord Drug Targets; 2018; 18(2):96-104. PubMed ID: 28820067
[TBL] [Abstract][Full Text] [Related]
8. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
Tshiani Mbaya O; Mukumbayi P; Mulangu S
Front Immunol; 2021; 12():721328. PubMed ID: 34526994
[TBL] [Abstract][Full Text] [Related]
9. Perspectives towards antiviral drug discovery against Ebola virus.
Mirza MU; Vanmeert M; Ali A; Iman K; Froeyen M; Idrees M
J Med Virol; 2019 Dec; 91(12):2029-2048. PubMed ID: 30431654
[TBL] [Abstract][Full Text] [Related]
10. Treatment of ebola virus disease.
Kilgore PE; Grabenstein JD; Salim AM; Rybak M
Pharmacotherapy; 2015 Jan; 35(1):43-53. PubMed ID: 25630412
[TBL] [Abstract][Full Text] [Related]
11. Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.
Kroeker A; Griffin BD; Qiu X; Kobinger G
Methods Mol Biol; 2017; 1628():273-282. PubMed ID: 28573628
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
mBio; 2019 May; 10(3):. PubMed ID: 31138743
[TBL] [Abstract][Full Text] [Related]
13. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP
Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038
[TBL] [Abstract][Full Text] [Related]
14. Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.
Shrivastava-Ranjan P; Flint M; Bergeron É; McElroy AK; Chatterjee P; Albariño CG; Nichol ST; Spiropoulou CF
mBio; 2018 May; 9(3):. PubMed ID: 29717011
[TBL] [Abstract][Full Text] [Related]
15. Modelling Ebola virus dynamics: Implications for therapy.
Martyushev A; Nakaoka S; Sato K; Noda T; Iwami S
Antiviral Res; 2016 Nov; 135():62-73. PubMed ID: 27743917
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin.
Covés-Datson EM; Dyall J; DeWald LE; King SR; Dube D; Legendre M; Nelson E; Drews KC; Gross R; Gerhardt DM; Torzewski L; Postnikova E; Liang JY; Ban B; Shetty J; Hensley LE; Jahrling PB; Olinger GG; White JM; Markovitz DM
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007595. PubMed ID: 31356611
[TBL] [Abstract][Full Text] [Related]
17. Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga.
Chiramel AI; Banadyga L; Dougherty JD; Falzarano D; Martellaro C; Brees D; Taylor RT; Ebihara H; Best SM
J Infect Dis; 2016 Oct; 214(suppl 3):S355-S359. PubMed ID: 27511894
[TBL] [Abstract][Full Text] [Related]
18. Treatment-focused Ebola trials, supportive care and future of filovirus care.
Keshtkar-Jahromi M; Martins KAO; Cardile AP; Reisler RB; Christopher GW; Bavari S
Expert Rev Anti Infect Ther; 2018 Jan; 16(1):67-76. PubMed ID: 29210303
[TBL] [Abstract][Full Text] [Related]
19. Progression of Ebola Therapeutics During the 2014-2015 Outbreak.
Mendoza EJ; Qiu X; Kobinger GP
Trends Mol Med; 2016 Feb; 22(2):164-173. PubMed ID: 26774636
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo.
Pessi A; Bixler SL; Soloveva V; Radoshitzky S; Retterer C; Kenny T; Zamani R; Gomba G; Gharabeih D; Wells J; Wetzel KS; Warren TK; Donnelly G; Van Tongeren SA; Steffens J; Duplantier AJ; Kane CD; Vicat P; Couturier V; Kester KE; Shiver J; Carter K; Bavari S
Antiviral Res; 2019 Nov; 171():104592. PubMed ID: 31473342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
